Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 77Pancreatic Neoplasms 56Stomach Neoplasms 52Rectal Neoplasms 43Esophageal Squamous Cell Carcinoma 38Esophageal Neoplasms 38Neoplasm Metastasis 25Colonic Neoplasms 23Neoplasms 15Cholangiocarcinoma 13Liver Neoplasms 10Gastrointestinal Neoplasms 10Breast Neoplasms 9Adenocarcinoma Of Esophagus 9Carcinoma, Hepatocellular 7Anus Neoplasms 7Lung Neoplasms 6Head and Neck Neoplasms 6Biliary Tract Neoplasms 6Ovarian Neoplasms 5Melanoma 5Adenocarcinoma 5Kidney Neoplasms 4Gastrointestinal Diseases 4Digestive System Neoplasms 4Carcinoma, Squamous Cell 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 3Sarcoma 3Lymphoma 3

Interventions

Trastuzumab 5Oxaliplatin 4Capecitabine 3trastuzumab deruxtecan 2tislelizumab 2disitamab vedotin 2Tegafur 2Fluorouracil 2Cisplatin 2tucatinib 1pembrolizumab 1S 1 (combination) 1Ramucirumab 1Paclitaxel 1HMPL-013 1Drug Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Gastric Cancer × Drug Therapy × Gastrointestinal × Clear all
NCT05311189 2022-04-05

Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer

Shanghai Zhongshan Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡